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The gaseousmessenger nitric oxide (NO) contributes to biological
effects of oestrogen in target tissues, including reproductive
organs, bone, cardiovascular and central nervous systems. Vaso-
dilation and anti-atherosclerotic properties of NO have been
shown to play a role in these effects. The possibility that NO acts
also through regulation of the signal transduction cascade trig-
gered by oestrogen, instead, has never been investigated. To
study this we have used the MCF-7 human breast cancer cell line,
an established model for oestrogen signalling. Exposure of these
cells to 17-b-oestradiol (E
#
) in the presence of NO gave rise to
activation of signalling events additional to those triggered by
E
#
alone, namely tyrosine phosphorylation of specific proteins,
including the insulin receptor substrate-1, with recruitment to
this adapter of the phosphatidylinositol 3«-kinase and persistent
activation of Akt (protein kinase B). Active Akt, in turn, pre-
vented E
#
from activating p42}44 extracellular signal-regulated
kinases (ERK 1}2). These effects of NO, which were mediated
INTRODUCTION
Oestrogen exerts multiple physiological and pathological effects.
On the one hand, it is essential to development and maintenance
of reproductive organs; on the other, it may sustain growth of
tumours that arise from these tissues [1]. In addition, oestrogen
contributes to regulation of the structure of the bone, and to
functioning of the cardiovascular and central nervous system [1].
These actions are mediated through activation of various recep-
tors,which include the classical nuclear receptors [1] and receptors
at the plasma membrane, whose molecular identity has not yet
been fully elucidated [2–5]. Heterogeneity of receptors may ex-
plain why oestrogen, together with the well-known ability to
initiate gene transcription at the oestrogen responsive elements
(ERE), often triggers complex patterns of intracellular signals
switched on from the first minutes after hormone administration.
These non-genomic actions include activation of adenylate
cyclase and phospholipase Cb, mobilization of intracellular
calcium, regulation of ion channels, activation of both the
phosphatidylinositol 3«-kinase (PI3K)}protein kinase B (Akt)
pathway and the extracellular signal-regulated kinases (ERK
1}2) [6]. Also insulin receptor substrate 1 (IRS-1), a docking
Abbreviations used: Ab, antibody; 8 Br, 8-bromo; cGMP, cyclic GMP; DETA-NO, (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-
1,2-diolate ; DMEM, Dulbecco modified Eagle’s medium; E2, 17b-oestradiol ; ECL2, enhanced chemiluminescence; ERE, oestrogen-responsive element ;
ERK 1/2, p42/44 extracellular signal-regulated kinases ; IGF-1 and IGF-1R, insulin-like growth factor 1 and its receptor ; IRS-1, insulin receptor substrate
1 ; mAb, monoclonal antibody; MAP kinase, mitogen-activated protein kinase ; MEK, MAP kinase/ERK kinase ; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide ; NO, nitric oxide ; NOS, NO synthase; ODQ, H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; PI3K, phosphatidylinositol
3«-kinase.
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through generation of cyclic GMP and activation of the cGMP-
dependent protein kinase I, initiated in the first minutes after
administration of oestrogen. The consequences, however, were
long lasting, as modulation of Akt and ERK 1}2 activities by
NO was responsible for inhibition of E
#
-triggered cell growth
and regulation of oestrogen responsive-element dependent gene
transcription. Generation of NO is stimulated by both E
#
and
growth factors known to contribute to the complex network of
intracellular events regulating the biological actions of oestrogen.
It is conceivable, therefore, that modulation by NO of E
#
early
signalling, here described for the first time, has broad significance
in regulating cellular responses to the hormone.
Key words: Akt, mitogen-activated protein (MAP) kinases, NO,
oestrogen responsive elements, phosphatidylinositol 3«-kinase,
protein kinase.
protein which acts as a major substrate for growth factors, may
be involved in oestrogen signalling [7–11]. This, however, has
been reported to occur only in the presence of growth factors, or
after long exposure to oestrogen, conditions in which IRS-1
contributes to the cross-talk between the steroid and insulin or
insulin-like growth factor-1 (IGF-1) [8–11].
Increasing evidence indicates that an effector molecule cru-
cial for oestrogen signalling is the short-lived messenger nitric
oxide (NO). NO participates in cardio-protective and anti-
atherosclerotic effects of oestrogen, as well as in the effects of the
steroid in the central nervous system and bone metabolism. Until
now these effects have been mostly attributed to direct actions of
NO on target tissues, including its well-known vasodilating and
anti-atherogenic properties [12]. However, the observation that
oestrogen not only increases expression of NO synthesizing
enzymes (NOS) [13], but also triggers direct activation of
endothelial NOS in the first minutes after its addition to cells
[3,4,14–16], opens the possibility that part of the NO effects on
oestrogen biological actions are also mediated through regulation
of the signal transduction cascades initiated by the hormone. So
far, this possibility has never been investigated.
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In the present work we have used an established model for
studies on oestrogen signalling, the human breast cancer cell line
MCF-7, exposed to 17b-oestradiol (E
#
) and the NO donor (Z )-1-
[2-(2-aminoethyl)-N-(2-ammonioethyl)aminodiazen]-1-ium-1,2-
diolate (DETA-NO). Our results show that NO renders E
#
competent to trigger rapid tyrosine phosphorylation, and thus
activation, of IRS-1. This initiates a complex chain of events that
include recruitment of PI3K, persistent activation of Akt and
ensuing inhibition of E
#
-triggered ERKs activation. These effects
of NO on E
#
signalling were found to be mediated through activ-
ation of guanylate cyclase, generation of cyclic GMP (cGMP)
and ensuing stimulation of the cGMP-dependent protein kinase I
(G kinase), and to have long-lasting consequences on cellular
responses to the steroid.
EXPERIMENTAL
Materials
The following reagents were purchased as indicated: H-[1,2,4]-
oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and KT5823 from
Calbiochem, Darmstadt, Germany; the Enhanced Chemi-
Luminescence (ECL2) kit from Amersham, Little Chalfont,
U.K.; DETA-NO from Alexis Co., Nottingham, U.K.; poly-
clonal antibodies (Ab) anti-Akt and anti-phospho-Akt (Ser 473),
monoclonal Ab (mAb) anti-p42}p44 ERK 1}2 and anti-
phospho-ERK 1}2 (Thr 202–Tyr 204) from New England
Biolabs, Beverly, MA, U.S.A. ; mAbs anti-phosphotyrosine
(PY20; horseradish peroxidase-conjugated), anti-p85 (PI3K
regulatory subunit), anti-endothelial NOS, anti-inducible NOS
and anti-neuronal NOS from Transduction Laboratories,
Lexington, KY, U.S.A. ; anti-rat carboxy-terminal IRS-1 poly-
clonal Ab from Upstate Biotechnology, Lake Placid, NY,
U.S.A. ; anti-IGF-1 receptor (IGF-1R) mAb from Santa Cruz
Biotechnology Inc., Santa Cruz, CA, U.S.A. ; calf serum,
tissue culture reagents and media from Mascia Brunelli, Milan,
Italy. Anti-oestrogen ICI 182,780 was kindly provided by
Zeneca, Macclesfield, U.K., and the EREtkLuc plasmid by Dr
M. Maggiolini, Dept of Pharmaco-Biology, University of
Calabria, Rende, Italy. E
#
and all the other reagents were
purchased from Sigma.
Cell cultures and preparation
MCF-7 cells, provided by Dr Eva Surmacz (Kimmel Cancer In-
stitute, Thomas Jefferson University, Philadelphia, PA, U.S.A.),
were routinely cultured in Dulbecco’s modified Eagle’s medium
(DMEM)}F12 (1:1) supplemented with 5% calf serum in a 5%-
CO
#
humidified atmosphere. These cells were chosen not only
because they are an established model for E
#
signalling, but
also because they are devoid of any detectable NOS, as demon-
strated by both Western blotting (Figure 1) and measurements
of NOS activity, carried out as described previously [17]. At the
time of experiments, subconfluent cell cultures were detached by
trypsinization, cultured in growth medium for 24 h and then for
an additional 24 h in DMEM without Phenol Red and serum.
Experiments were carried out using 70% confluent cells in
DMEM without Phenol Red and serum. All incubations with
the various compounds were for 15 min prior to addition of E
#
(time 0).
Immunoprecipitation and Western blotting
Cells, incubated with the various compounds as detailed in the
results, were treated with E
#
and washed twice, at the indicated
time points, with a cold buffer [150 mM NaCl, 1.5 mM MgCl
#
,
Figure 1 MCF-7 cells do not express NOS isoforms
Expression of endothelial, neuronal and inducible NOS was analysed by Western blotting with
specific Abs on 40 lg of cell lysates from subconfluent MCF-7 cells, as detailed in the
Experimental section. Positive controls for each NOS isoform (20 lg of lysates from human
aortic endothelial cells, rat pituitary cells and activated RAW 264.7 macrophages, for endothelial
neuronal and inducible NOS, respectively, all provided by Transduction Labs together with the
Abs) were loaded in parallel. The experiments shown are representative of three.
1 mM EGTA, 10% (v}v) glycerol, 50 mM Hepes, pH 7.5]. Cells
were then lysed for 30 min in the same buffer with the addition of
0.1 mM PMSF, 1% (v}v) Triton X-100, 0.2 mM orthovanadate,
10 lg}ml leupeptin and 10 lg}ml aprotinin (lysis buffer). For
immunoprecipitation, lysateswere centrifuged at 800 g for 15 min
and the supernatants incubated overnight at 4 °C with 4 lg of
either anti-IRS-1 Ab or anti-IGF-1R Ab. Protein G–Sepharose
beads were then added to the lysates, which were incubated
overnight and then washed three times with the above lysis buffer
(see [18] for further details). Protein concentrations in the lysates
and immunoprecipitates were assayed using the bicinchoninic
acid procedure (Pierce, Rockford, IL, U.S.A.). Western-blot
analyses were carried out with either 500 lg of immunoprecipi-
tates or 40 lg of total protein, which were first separated on
pre-cast 4–15% gradient SDS}polyacrylamide gels (Bio-Rad,
Milan, Italy) and then electrophoretically transferred on to
nitrocellulose membranes (Schleicher and Schuell, Dassel,
Germany). Non-specific sites were blocked before immunolabel-
ling by incubation for 1 h at 21 °C with blotting buffer [100 mM
Tris}HCl, 0.1% Tween 20 and 5% (w}v) non-fat milk, pH 7.4].
The membranes were incubated overnight in blotting buffer
with the relevant Ab and washed three times for 1 h with
blotting buffer. The secondary anti-rabbit or anti-mouse horse-
radish peroxidase conjugated Ab was then added for 30 min.
After several washes of the membranes in blotting buffer, the
antigens were revealed with ECL2 according to the manu-
facturer’s instructions. As an internal control, all Western blots
in which the phosphorylation levels of either Akt or ERK 1}2
were determined, were subsequently stripped of the first Ab and
reprobed with the Ab recognizing both the phosphorylated and
non-phosphorylated forms of the enzyme. Similarly, Western
blots of IRS-1 and IGF-1R immunoprecipitates analysed with
the anti-p85 or anti-phosphotyrosine Abs were reprobed with the
anti-IRS-1 Ab or the anti-IGF-1R Ab respectively. Stripping
of the first Ab was carried out by incubating nitrocellulose filters
for 30 min at 52 °C with a buffer [62.5 mM Tris}HCl, 2% (w}v)
SDS, 1% b-mercaptoethanol, pH 6.7]. Filters were then washed
twice for 10 min with 100 mM Tris}HCl, 0.1% Tween 20,
pH 7.4, before equilibration for 1 h in blotting buffer. Quanti-
tation of the relevant bands was carried out using a Quick Image
densitometer equipped with a Phoretix 1-D software image
analyser (Canberra Packard, Milan, Italy).
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Transfections and luciferase assay
MCF-7 cells were plated at a concentration of 1‹10& cells}well
the day before transfection into 24-well plates with 500 ll of
growthmedium.Themediumwas replacedwithDMEM(without
Phenol Red and serum) 1 h before transfection. Cells were trans-
fected using FuGENE 6 (Roche, Indianapolis, IN, U.S.A.)
according to the manufacturer’s instructions. The transfection
mixture contained 0.5 mg of EREtkLuc (also called XETL and
described in [19]), and 0.05 mg of the Renilla luciferase ex-
pression vector pRL-CMV (Promega Italia, Milan, Italy), used
as a internal control of transfection efficiency. MCF-7 cells
were incubated with the DNA mixtures for 8 h, washed and
cultured in DMEM (without Phenol Red and serum) for a
further 4 h. Cells were then treated with various compounds,
as indicated in the Results section, before addition of E
#
.
After 8 h, cells were lysed (see above procedure) and luciferase
activity was measured using a Dual-Luciferase reporter assay
system (Promega) according to the manufacturer’s instruction.
Luciferase values were divided by the correspondent Renilla
luciferase values and expressed as relative luciferase units.
Cell-proliferation assays
For the colorimetric assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) [20], MCF-7 cells were
plated in 24-multiwell plates at the concentration of 4‹10$ cells}
well in growth medium. After 2 days the medium was replaced
with DMEM (without Phenol Red and serum) for 24 h. Cells
were then incubated with various compounds, as detailed in the
Results section, and treated with E
#
. At the indicated time points
(days 1–3) cells were washed, 0.5 ml of MTT stock solution
(2.4 mM in DMEM without Phenol Red, filtered) was added,
and the plates were incubated for 1 h at 37 °C. At the end
of the incubation the non-transformed MTT was carefully re-
moved and the dye crystals solubilized in 1 ml of 2-propanol.
Absorbances were read immediately in a UVKON 941 spec-
trophotometer using a test wavelength of 570 nm and a
reference wavelength of 690 nm.
Statistical analysis
The results are expressed as means‡standard error of the
mean; n represents the number of different experiments, which
were run in triplicate. Western-blotting data are representative of
3 to 4 experiments, as specified in each Figure legend. Statistical
analysis was performed by the Student’s t test for unpaired data
(two-tail). The symbols *, ** and *** or ›, ››, ››› in
Table 1 and Figure 8 refer to statistical probabilities (P) of
! 0.05, ! 0.01 and ! 0.001, respectively, as detailed in the
legend to Figure 8. A value of P less than 0.05 was considered
to be statistically significant.
RESULTS
The MCF-7 cells used in our experiments are devoid of any
detectable NOS, as detected by Western blotting with specific
Abs recognizing specifically the endothelial, the neuronal or the
inducible NOS (Figure 1). In addition, they display no NOS
activity, which was assessed by measuring arginine to citrulline
conversion as described previously [17] (results not shown).
Absence of endogenous NO generation makes these cells a clean
system to study the effects of NO. Experiments were carried out
using the NO donor DETA-NO which, at the concentration em-
ployed (100 lM), released NO at the constant concentration of
0.21‡0.2 lM (nfl 4), as measured by an NO electrode [21]. To
investigate the effects of NO on E
#
-induced tyrosine phosphoryl-
Figure 2 Effects of E2 and NO on protein tyrosine phosphorylation
Subconfluent MCF-7 cells were incubated for 15 min with or without DETA-NO (100 lM), ICI
182,780 (ICI, 100 nM) or both, as indicated on the left-hand side of each panel, before addition
of either E2 (1 nM) or vehicle (time 0). Cells were collected at the indicated time points, and
tyrosine phosphorylation of proteins measured with an anti-phosphotyrosine Ab on Western
blots of 40 lg of cell lysates, as detailed in the Experimental section. The positions and
molecular mass (kDa) of the molecular-mass markers used (Prestained molecular weight
marker, high range, Calbiochem) are indicated on the right-hand side of each panel. The
experiments shown are representative of four.
ation, sub-confluent MCF-7 cells were exposed to DETA-NO,
E
#
(1 nM) and the oestrogen antagonist ICI 182,780 (100 nM),
administered either alone or combined. Tyrosine phosphoryl-
ation was measured by Western blotting at different time
points after stimulation, as indicated in Figure 2. The effect of E
#
was relatively small and transient, as shown previously in these
cells [22]. DETA-NO did not have any effect when administered
alone. Combination of E
#
with DETA-NO, instead, resulted in
markedly enhanced tyrosine phosphorylation staining which, in
addition, became persistent throughout the time-window analy-
sed (1 h). In the presence of ICI 182,780, tyrosine phosphoryl-
ation was observed with E
#
neither when administered alone nor
when combined with DETA-NO (Figure 2, and results not
shown).
The pattern of tyrosine phosphorylation observed with E
#
and
NO included also proteins in the 150–190 kDa range, among
which is IRS-1. To verify the involvement of the latter, cells,
treated as above, were lysed and IRS-1 immunoprecipitated with
an anti-IRS-1 specific Ab. Tyrosine phosphorylation of the
precipitates was analysed by Western blotting. As shown in
Figure 3, E
#
and DETA-NO had no effect when given alone. By
contrast, when administered together, they induced tyrosine
phosphorylation of IRS-1, which was already present after 5 min
of treatment and maintained throughout the period analysed.
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Figure 3 Effects of E2, NO, cGMP and G kinase on tyrosine phosphorylation
of IRS-1
Subconfluent MCF-7 cells were incubated for 15 min with or without DETA-NO (100 lM), ICI
182,780 (ICI, 100 nM), 8 Br-cGMP (1 mM), ODQ (1 lM) or KT5823 (5 lM), in various combin-
ations as detailed on the right-hand side of each panel. Cells were collected at the indicated
time points after addition of E2 (1 nM) or vehicle (time 0), lysed and immunoprecipitated with
an anti-IRS-1 Ab. Tyrosine phosphorylation of IRS-1 was measured with an anti-phosphotyrosine
Ab (PY) on Western blots of 500 lg of immunoprecipitates (I.P. : a-IRS-1 ; I.B. : a-PY). As
control, the levels of IRS-1 in each immunoprecipitate was measured by reprobing each Western
blot with the anti-IRS-1 Ab (I.P. : a-IRS-1 ; I.B. : a-IRS-1). The experiments shown are
representative of four.
This tyrosine phosphorylation was not observed in the presence
of ICI 182,780.
NO may exert its effect either through activation of guanylate
cyclase, generation of cGMP and activation of G kinase or
through alternative pathways [23]. To establish whether NO was
acting in a cGMP-dependent manner, experiments were carried
out in the presence of the membrane-permeant cGMP analogue,
8-bromo (8 Br)-cGMP (1 mM), the guanylate cyclase inhibitor,
ODQ (1 lM), or the selective G kinase inhibitor KT5823 (5 lM)
[24]. 8 Br-cGMP mimicked the effect of DETA-NO, as it was in-
effective when given alone, while inducing tyrosine phosphoryl-
ation of IRS-1 in the presence of E
#
with kinetics similar to
those of the NO donor. Consistent with this observation, co-
incubation in the presence of ODQ abrogated the effect of DETA-
NO. Co-incubation in the presence of KT5823 also reversed the
effect of DETA-NO (Figure 3). To establish whether the effects
observed were due to actual changes in tyrosine phosphorylation
of IRS-1 or secondary to changes in IRS-1 protein levels, all
Western blots were stripped of the anti-tyrosine Ab and decorated
with the anti-IRS-1 Ab. No changes in IRS-1 protein were
observed in all cases (Figure 3). Taken together, these results
indicate that NO and E
#
synergize to induce tyrosine phosphoryl-
Figure 4 Effects of E2 and NO on tyrosine phosphorylation of IGF-1R
Subconfluent MCF-7 cells were incubated for 15 min with or without DETA-NO (100 lM) before
addition of either E2 (1 nM) or vehicle (time 0). Cells were collected at the indicated time points,
lysed and immunoprecipitated with an anti-IGF-1R Ab. Tyrosine phosphorylation of IGF-1R
was measured with an anti-phosphotyrosine Ab (PY) on Western blots of 500 lg of
immunoprecipitates (I.P. : a-IGF-1R ; I.B. : a-PY). As control, the level of IGF-1 R in each
immunoprecipitate was measured by reprobing each Western blot with the anti-IGF-1R Ab (I.P. :
a-IGF-1R ; I.B. : a-IGF-1R). 10 min stimulation of MCF-7 cells with IGF-1 (1 nM) was carried
out in parallel as positive control for IGF-1R tyrosine phosphorylation. The experiments shown
are representative of three.
ation of IRS-1 and that the effect of the gaseous messenger is
dependent on generation of cGMP and activation of G kinase.
IRS-1 is a major substrate for IGF-1R, and its tyrosine phos-
phorylation contributes significantly to the cross-talk between
the signalling pathways activated by this receptor and E
#
. In par-
ticular, IRS-1 tyrosine phosphorylation, induced by activation
of IGF-1R with either IGF-1 or insulin, appears to be enhanced
in the presence of E
#
[9–11]. We investigated, therefore, whether
synergism between NO and E
#
in triggering tyrosine phosphoryl-
ation of IRS-1 was due to activation of IGF-1R. To this end, cells
were exposed to E
#
, DETA-NO, or the two together, and IGF-1R
tyrosine phosphorylation analysed after receptor immunoprecipi-
tation with an anti-IGF-1R specific Ab. At variance with IGF-1,
which induced marked IGF-1R phosphorylation after 10 min
treatment, E
#
was ineffective both when administered alone (as
already shown in MCF-7 cells, see [9,10] and when combined
with DETA-NO (Figure 4). The amount of IGF-1R protein
precipitated by the anti-IGF-1R Ab, however, was the same in
all conditions (Figure 4). These results indicate that IGF-1R is




IRS-1 acts as an adapter to various downstream effector
molecules, among which is PI3K, whose recruitment and activa-
tion is increased following IRS-1 tyrosine phosphorylation
[25–27]. Recruitment of the PI3K p85 regulatory subunit to IRS-1
was therefore analysed. After administration of E
#
and NO,
either alone or combined, IRS-1 was immunoprecipitated and
the amount of co-precipitated p85 detected by Western blotting.
Treatment with either DETA-NO or E
#
alone revealed no p85
co-precipitation. By contrast, this was clearly observed when the
two stimuli were applied together (Figure 5). The amount of
IRS-1 protein immunoprecipitated was the same in all condi-
tions (Figure 5).
To investigate whether recruitment of p85 to IRS-1 induced by
the combination of NO and E
#
resulted in stimulation of PI3K
activity we examined activation of a well-known downstream ef-
fector of this enzyme, i.e. Akt, using an Ab recognizing select-
ively the phosphorylated, active form of the protein (Figure 6).
E
#
induced activation of Akt which, however, was transient (up
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Figure 5 Effects of E2 and NO on the recruitment of the p85 regulatory
subunit of PI3K to IRS-1
Subconfluent MCF-7 cells were incubated for 15 min with or without DETA-NO (100 lM) before
addition of either E2 (1 nM) or vehicle (time 0). Cells were collected at the indicated time points,
lysed and immunoprecipitated with an anti-IRS-1 Ab. Co-immunoprecipitation of p85 together
with IRS-1 was measured by Western blotting on 500 lg of immunoprecipitates, using an anti-
p85 Ab (I.P. : a-IRS-1 ; I.B. : a-p85). The level of IRS-1 in each immunoprecipitate was
measured by reprobing each Western blot with the anti-IRS-1 Ab (I.P. : a-IRS-1 ; I.B. : a-IRS-1).
The experiments shown are representative of four.
Figure 6 Effects of E2, NO, cGMP and G kinase on activation of Akt
Subconfluent MCF-7 cells were incubated for 15 min with or without DETA-NO (100 lM), ICI
182,780 (ICI, 100 nM), wortmannin (wort, 20 nM), 8 Br-cGMP (1 mM), ODQ (1 lM) or
KT5823 (5 lM), in various combinations as detailed on the right-hand side of each panel. Cells
were collected at the indicated time points after addition of E2 (1 nM) or vehicle (time 0), lysed
and samples (40 lg) analysed by Western blotting with an Ab recognizing phosphorylated
(Ser 473) Akt (active Akt). As control, each Western blot was reprobed with an Ab recognizing
both phosphorylated and non-phosphorylated Akt (total Akt). The experiments shown are
representative of four.
Figure 7 Effects of E2, NO, cGMP and G kinase on activation of ERK 1/2
Subconfluent MCF-7 cells were incubated for 15 min with or without ICI 182,780 (ICI, 100 nM),
PD 98059 (PD, 30 lM), DETA-NO (100 lM), 8 Br-cGMP (1 mM), ODQ (1 lM), KT5823
(5 lM), or wortmannin (wort, 20 nM), in various combinations as detailed on the right-hand
side of each panel. Cells were collected at the indicated time points after addition of E2 (1 nM)
or vehicle (time 0), lysed and samples (40 lg) analysed by Western blotting with an Ab
recognizing phosphorylated (Thr 202–Tyr 204) ERK 1/2 (active ERK 1/2). As control, each
Western blot was reprobed with an Ab recognizing both phosphorylated and non-phosphorylated
ERK 1/2 (total ERK 1/2). Ratios of densitometric values measured for active ERK 1/2 to total
ERK 1/2 are reported in Table 1.The experiments shown are representative of four.
to 15 min). DETA-NO did not have an effect per se, but
enhanced Akt activation by E
#
; significantly, both in intensity
and duration. This effect was abolished when cells were incubated
with either ICI 182,780 or a PI3K inhibitor, namely wortmannin
(20 nM) or LY 294002 (10 lM), indicating the involvement of
the oestrogen receptor and PI3K (Figure 6 and results not
shown). The effect of DETA-NO was mimicked by 8 Br-cGMP
and reversed by either ODQ or KT5823, demonstrating also that
Akt activation by NO in the presence of E
#
depends on cGMP
generation and G kinase activation. When Western blots, used to
reveal active Akt, were decorated with an Ab recognizing both
the active and inactive protein, no difference in total Akt levels
was detected in all condition tested (Figure 6). Thus, NO appears
capable of enhancing Akt activation by E
#
through the IRS-1}
PI3K pathway, turned on in a cGMP}G kinase-dependent
fashion.
An early signalling event triggered independently by both E
#
and NO, the latter acting through the cGMP}G kinase path-
way, is activation of ERK 1}2 [28–32]. The effects of E
#
and
DETA-NO on ERK 1}2 activation were therefore investigated
by using Abs recognising specifically either total ERK 1}2 or its
phosphorylated, active form. Both E
#
and DETA-NO, when
administered alone, induced activation of ERK 1}2, which was
persistent throughout the time window analysed (Figure 7 and
Table 1). ERK 1}2 activation was inhibited in both cases by co-
administration of the MEK (MAP kinase}ERK kinase) inhibitor
PD 98059 (30 lM), indicating involvement of this enzyme in
ERK 1}2 activation. The effect of E
#
was prevented by ICI
182,780. When we examined the effects of the combined adminis-
tration of E
#
and NO we found that they were not additive
but gave rise to complete abrogation of ERK 1}2 activation.
Both the stimulation of ERK 1}2 by NO and their inhibition
in the presence of E
#
were found to be dependent on gener-
ation of cGMP and activation of G kinase, as these effects of
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Table 1 Effects of E2, NO, cGMP and G kinase on activation of ERK 1/2 measured as the ratio of active to total ERK 1/2
Subconfluent MCF-7 cells were incubated for 15 min with or without ICI 182,780 (ICI, 100 nM), PD 98059 (PD, 30 lM), DETA-NO (100 lM), 8 Br-cGMP (1 mM), ODQ (1 lM), KT5823 (5 lM),
or wortmannin (wort, 20 nM), in various combinations as detailed in the left-hand column. Cells were collected at the indicated time-points after addition of E2 (1 nM) or vehicle (time 0), lysed
and samples (40 lg) were analysed by Western blotting with an Ab recognising phosphorylated, active ERK 1/2. Each Western blot was then reprobed with an Ab recognising both phosphorylated
and non-phosphorylated ERK 1/2. Blots were then analysed by densitometry. Shown are the ratios of the values‡standard error of the mean measured for active to total ERK 1/2 (n fl 4). Asterisks
indicate statistical significance versus treatments with E2 alone at the same time-points, calculated as described in the Experimental section.
Compound
Time (min)
0 5 15 30 60
E2 0.03‡0.01 0.41‡0.01 0.71‡0.03 0.82‡0.04 0.91‡0.06
E2›ICI 0.01‡0.01 0.02‡0.01 0.06‡0.01 0.03‡0.01 0.01‡0.00
E2›PD 0.02‡0.01 0.00‡0.00 0.04‡0.01 0.01‡0.01 0.03‡0.01
DETA-NO 0.03‡0.01 0.48‡0.02 0.88‡0.05 0.96‡0.04 0.97‡0.04
8 Br-cGMP 0.00‡0.00 0.32‡0.01 0.38‡0.01 0.68‡0.03 0.66‡0.03
DETA-NO›E2 0.03‡0.01 0.05‡0.01 0.00‡0.01 0.04‡0.01 0.01‡0.01
8 Br-cGMP›E2 0.01‡0.01 0.07‡0.01 0.10‡0.01 0.06‡0.01 0.09‡0.01
DETA-NO›E2›ODQ 0.04‡0.01 0.56‡0.04 0.78‡0.06 0.86‡0.05 1.07‡0.08
DETA-NO›E2›KT5823 0.02‡0.01 0.51‡0.02 0.83‡0.04 0.88‡0.06 0.93‡0.09
DETA-NO›E2›wort 0.00‡0.00 0.48‡0.04 0.80‡0.05 1.09‡0.04** 1.22‡0.03**
NO were mimicked by 8 Br-cGMP and reversed by either ODQ
or KT5823 (Figure 7, Table 1 and results not shown).
The mechanism of inhibition of ERK 1}2 in the presence of
NO}cGMP and E
#
was next investigated. ERK 1}2 are inhibited
by stimulation of the PI3K}Akt pathway [33]. Since this pathway
is activated in the presence of NO}cGMP and E
#
(Figures 3 and
4), we assessed its involvement in inhibition of ERK 1}2. When
cells were exposed to E
#
together with either DETA-NO or
8 Br-cGMP, and in the presence of wortmannin or LY 294002,
ERK 1}2 activation was restored, with enzyme activation greater
than that observed with E
#
, DETA-NO or 8 Br-cGMP alone
(Figure 7, Table 1 and results not shown). These results suggest
strongly that the inhibition of ERK 1}2 in the presence of NO}
cGMP and E
#
is due to concomitant PI3K}Akt activation.
PI3K}Akt and ERK 1}2 have been shown to enhance the E
#
-
induced stimulation ofERE-containing genes [34,35]. To evaluate
whether the regulation of PI3K}Akt and ERK 1}2 pathways
described above influences the ability of E
#
to activate ERE-
dependent transcription, cell were transiently transfected with a
luciferase reporter gene under the control of a ERE element
(EREtkLuc, described in [19]). Exposure to E
#
for 8 h induced
EREtkLuc expression, with ensuing luciferase expression, which
was abolished by co-incubation with ICI 182,780 (Figure 8A).
Treatment with PD 98059, wortmannin, or LY 294002 resulted
in inhibition of E
#
effects on EREtkLuc, that was more pro-
nounced when PD 98059 and either PI3K inhibitor were both
present (Figure 8A and results not shown).
We then examined the effects of DETA-NO and 8 Br-cGMP.
Results were similar with both compounds, therefore only those
obtained with 8 Br-cGMP are described in detail (Figure 8A).
The cyclic nucleotide had no effects on EREtkLuc. Likewise, it
did not modify EREtkLuc response to E
#
administration when
co-administered with the steroid. As demonstrated above, how-
ever, E
#
signalling is profoundly modified by cGMP, with
PI3K}Akt greatly stimulated and ERK 1}2 inhibited. We
investigated the role of these changed kinase activities. In the
presence of wortmannin or LY 294002, luciferase expression
induced by co-administration of 8 Br-cGMP with E
#
was not
modified, presumably because of the concomitant greater activ-
ation of ERK 1}2 observed when PI3K inhibitors are adminis-
tered prior to 8 Br-cGMP and E
#
(see above). Consistently,
addition of PD 98059 together with either wortmannin or LY
294002 inhibited to a great extent luciferase expression induced
by co-administration of 8 Br-cGMP with E
#
, with values similar
to those observed with E
#
in the presence of PD 98059 and either
PI3K inhibitor (Figure 8A and results not shown). This suggests
that PI3K}Akt activation and concomitant ERK 1}2 inhibition




Activation of ERK 1}2 and gene transcription are relevant to
mitogenic effects of E
#
[35–37]. We therefore evaluated whether
the NO-induced, cGMP-dependent regulation of E
#
signalling
influences the mitogenic properties of the steroid. Since NO also
acts on growth independently of cGMP ([24] and references
therein), we analysed specifically the effect of the cyclic nucleotide.
Cell proliferation was measured using an established technique,
i.e. conversion of MTT into its derivative, formazan [20].
Administration of E
#
induced cell proliferation, which was
completely inhibited by ICI 182,780. Blockade of ERK 1}2 acti-
vation with PD 98059 resulted in reduced E
#
-dependent cell
proliferation, whereas wortmannin or LY 294002 modified the




plus PD 98059 (Figure 8B, and results
not shown). These results are consistent with the involvement of
ERK 1}2 in E
#
-induced cell proliferation already described in
these cells [37]. 8 Br-cGMP itself induced a small, yet significant
increase in cell proliferation (Figure 8B). The effect of the cyclic





and 8 Br-cGMP were administered together,
cell proliferation was inhibited to a large extent. This inhibition
was likely due to PI3K}Akt-dependent inhibition of ERK 1}2, as
it failed to appear when 8 Br-cGMP and E
#
were administered in
the presence of wortmannin or LY 294002 (Figure 8B and results
not shown). Consistent with this, administration of E
#
and 8 Br-
cGMP together with PD 98059 did not result in further inhibition
(Figure 8B). These results indicate that regulation by NO}cGMP
of E
#
signalling pathways results in modulation of one of the
important functions of the steroid, i.e. cell proliferation.
DISCUSSION
A fascinating aspect of E
#
is its ability to trigger complex patterns
of cell responses that contribute to co-ordinate growth, de-
velopment and differentiation of organs as diverse as those
forming the reproductive systems of both females and males,
mammary glands, bone, cardiovascular and central nervous
systems. The discovery that E
#
interacts with distinct membrane
and nuclear receptors to trigger both rapid signal transduction
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Figure 8 Effects of E2 and cGMP on activation of ERE-dependent
transcription and cell proliferation
(A) Subconfluent MCF-7 cells, transiently transfected with EREtkLuc, were incubated for 15 min
with or without ICI 182,780 (ICI, 100 nM), PD 98059 (PD, 30 lM), wortmannin (wort, 20 nM)
or 8 Br-cGMP (1 mM) in various combinations as detailed on the left-hand side. Cells were then
incubated for a further 8 h with either E2 (1 nM) or vehicle, after which luciferase activity was
determined as detailed in the Experimental section. The normalized luciferase activity of the
unstimulated cells was arbitrarily assigned the value of 1 (control). Values are expressed as fold
increase over control‡standard error of the mean. (B) MCF-7 cells, incubated as indicated
in (A), were treated with or without E2 for 1–3 days, after which the MTT assay was carried out
as described in the Experimental section. Absorbances were measured using a test wavelength
of 570 nm and a reference wavelength of 690 nm. In both panels, statistical probability versus
untreated controls is indicated by the asterisks, that versus cells treated with E2 alone with
crosses, and both calculated as described in the Experimental section (n fl 6).
events and more prolonged regulation of gene transcription, and
that these signals integrate and partially overlap with those of
growth factors and cytokines, provides a molecular explanation
to such complex effects of the steroid [1,6]. The efficiency of E
#
signalling, however, together with the pathological consequences
arising from its disregulation (tumours, for example) suggest that
its signal transduction pathways are exquisitely co-ordinated.
Our results show that NO contributes substantially to such co-
ordination, in analogy with similar actions by NO on signalling
pathways activated by other receptor agonists [17,38].
Indeed, NO modifies profoundly the whole pattern of early
signalling events triggered by E
#
. A first effect is that of increasing
E
#
ability of phosphorylating proteins on tyrosine. In particular,
in the presence of NO, E
#
becomes competent to induce an early
(min) phosphorylation, and thus activation, of IRS-1. We have
investigated possible mechanisms underlying such effect of NO.
Previous reports indicated that tyrosine phosphorylationof IRS-1
in the presence of E
#
occurs as a consequence of synergistic action
between the hormone and agonists of IGF-1R [9–11]. Our results,
however, indicate that the involvement of this receptor in me-
diating the effects of NO is unlikely, because co-administration
of E
#
and NO did not result in increased IGF-1R activation.
In contrast, we found that the effect of NO is mediated through
generation of cGMP and activation of G kinase, a member of the
serine}threonine family of protein kinases known to mediate
several physiological effects ofNO [23]. Phosphorylation of IRS-1
by other members of this family of kinases, namely protein
kinase Cs, Akt [possibly via activation of mTOR (mammalian
target of rapamycin)], stress and mitogen-activated protein
kinases, was shown in various cell systems. This resulted, how-
ever, in impairment of IRS-1 function [39–42]. The ability of
G kinase to activate, rather than inhibit, IRS-1 function
might be due to direct phosphorylation on specific sites dif-
ferent from those affected by these other kinases, or mediated
through phosphorylation of intermediate, as yet unidentified,
molecules.
Until now involvement of IRS-1 in signalling by E
#
had been
recognized tobe limited to specific conditions, because it appeared
to require either long-term exposure to the steroid, with increased
expression of the adapter, or the combined administration of E
#
with insulin and IGF-1 [8–11]. The finding that NO enables
activation of IRS-1 by E
#
independently of IGF-1R activation
suggests that the role for the adapter in oestrogen signalling is
broader than previously recognized. In particular, IRS-1 might be
ordinarily involved in transducingE
#
signals in cells endowedwith
the E
#
-activatable, endothelial NOS. This is of biological rele-
vance in view of our findings that IRS-1, when activated, is central
to regulation of the signalling pathways activated by E
#
.
The first important consequence of IRS-1 involvement in E
#
signalling is the recruitment of PI3K and the ensuing activation of
Akt. A stimulation of Akt by E
#
due to direct interaction of PI3K
with the oestrogen receptor, i.e. without involvement of IRS-1,
has already been described [4,15,16]. We found, however, that the
two modes of Akt activation, i.e. IRS-1-dependent and indepen-
dent, differ profoundly in terms of kinetics. IRS-1-independent
activation is small and transient (see also [4] and [15]), whereas
that induced by recruitment of IRS-1 through the NO}cGMP}
G kinase pathway is persistent and more conspicuous.
There are important implications of this persistent Akt activ-
ation. Akt is a messenger through which E
#
activates endo-
thelial NOS to generate NO [4,16]. In cells endowed with this
enzyme NO might therefore act in a Akt-centred, feed-forward
loop aimed at amplifying the initial steps of E
#
signalling. In
addition, Akt has been recently shown to be among the signals
through which various growth factors trigger phosphorylation of
the activation function-1 domain of oestrogen receptor a, thereby
enhancing receptor activity [43]. This, together with the observ-
ation that growth factors also generate NO}cGMP [38] suggests
that the gaseous messenger does contribute substantially to the
cross-talk between the signalling pathways activated by E
#
and
growth factors. This might be of relevance in view of the regu-
latory role that such cross-talk plays in modulating biological
functions of tissues target of oestrogen [1].
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Change in ERK 1}2 function is another important conse-
quence of the E
#
}NO-induced recruitment to E
#
signalling of the
IRS-1–PI3K}Akt pathway. Activation of ERK 1}2, which is
marked when either E
#
or NO}cGMP are administered indepen-
dently ([28–32], and this paper), was inhibited when they were
combined. This was consequent to activation of PI3K, because
inhibition of PI3K with either wortmannin or LY 294002 reverted
this effect, enabling additive activation of ERK 1}2 by the
steroid and the gaseous messenger. Akt stimulation by PI3K is
known to impair ERK 1}2 activation through inhibition of the
Raf proteins [33]. Since both E
#
and NO (via G kinase) activate
ERK 1}2 through the Raf}MEK pathway ([28,31,32] and this
paper), it is conceivable that Akt-dependent inhibition of Raf is
the mechanism underlying the switch-off of ERK 1}2 stimulation
observed in the presence of E
#
and NO. Activation of ERK 1}2
is relevant to mitogenic effects of E
#
[37], which, however, involve
not only physiological stimulation of growth but also its tumouri-
genic development, especially in reproductive organs [1]. Activ-
ation of the NO}cGMP pathway by E
#
, and ensuing inhibition
of ERK 1}2, might therefore contribute to regulate E
#
signalling
and inhibit generation of abnormal mitogenic signals. This hypo-
thesis is substantiated by the observation that MCF-7 cell growth
triggered by E
#
was inhibited in the presence of cGMP. This inhi-
bition was due to the cGMP-dependent blockade of ERK 1}2,
mediated via activation of the PI3K}Akt pathway.
Akt and ERK 1}2 phosphorylate oestrogen receptor a, thereby
enhancing the ability of E
#
to promote transcription of ERE-
containing genes [34,35,44]. Consistent with these observations
we found that inhibition of either kinase resulted in reduced
activation of ERE by E
#
, measured using the EREtkLuc reporter
gene. The IRS-1-dependent changes in PI3K}Akt and ERK 1}2
activities induced by the concomitant administration of NO}
cGMP together with E
#,
instead, did not modify significantly the
effects of E
#
on ERE, most likely because of the balance between
inhibition of ERK 1}2 and stimulation of Akt. Thus, while inhi-
biting E
#
-dependent cell growth, NO}cGMP appear to maintain
the ability of the steroid to stimulate gene transcription. It must
be noted, however, that gene transcription by E
#
involves inter-
action of oestrogen receptors with a vast array of co-activators
and co-repressors [45]. Direct effects of NO}cGMP on these
proteins, with changes in their ability to interact with oestrogen
receptors or target sequences, cannot be excluded by our experi-
ments. In addition, NO}cGMP activates the AP-1 transcription
complex, which may contribute to E
#
-dependent gene transcrip-
tion [24,46,47]. Thus, the combination of E
#
with NO}cGMP
might also lead to changes in expression of specific genes. E
#
sustains differentiation of target tissues, especially reproductive
organs, to which NO also contributes [1,48]. Cell growth and
gene expression are relevant to this function of the steroid. In view
of this, the dual action by NO on E
#
signalling described




Activation of IRS-1 by the combined action of E
#
and the NO-
stimulated cGMP}G kinase pathway may result in downstream
signalling events additional to those reported here. IRS-1 has
over 20 potential tyrosine-phosphorylation sites, which serve as
binding sites to a variety of SH2 domain-containing messenger
molecules [7]. Whether the pattern of tyrosine phosphorylation
induced by co-stimulation with E
#
and NO leads to recruitment
of PI3K}Akt only or also of any of these other effectors remains
to be investigated.
In conclusion, our results show that NO, through generation
of cGMP and activation of G kinase, modifies profoundly E
#
early signalling and contributes to regulate long-term actions
of the steroid. Generation of NO, formation of cGMP and
activation of G kinase is triggered in most cells by a variety
of receptors, including tyrosine kinase and G-protein-coupled
receptors, as well as receptors for cytokines, in both physiological
and pathological conditions [17,23,38]. It is conceivable, there-
fore, that the overall regulation of E
#
signalling by NO described
here is a common pathway regulating oestrogen biological
activity.
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